{"id":"https://openalex.org/W2166959486","doi":"https://doi.org/10.1111/j.1749-6632.2011.05974.x","title":"A review of the history, properties, and use of the immunomodulatory compound lenalidomide","display_name":"A review of the history, properties, and use of the immunomodulatory compound lenalidomide","alternate_titles":[],"publication_year":2011,"publication_date":"2011-03-01","ids":{"openalex":"https://openalex.org/W2166959486","doi":"https://doi.org/10.1111/j.1749-6632.2011.05974.x","mag":"2166959486","pmid":"https://pubmed.ncbi.nlm.nih.gov/21434945"},"language":"en","primary_location":{"id":"doi:10.1111/j.1749-6632.2011.05974.x","doi":"https://doi.org/10.1111/j.1749-6632.2011.05974.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1749-6632.2011.05974.x","pdf_url":null,"source":{"id":"https://openalex.org/S8802318","display_name":"Annals of the New York Academy of Sciences","issn_l":"0077-8923","issn":["0077-8923","1749-6632"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the New York Academy of Sciences","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2166959486"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5055075571","display_name":"Jerome B. Zeldis","orcid":"https://orcid.org/0000-0002-0184-0672","observed_orcids":["https://orcid.org/0000-0002-0184-0672"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Jerome B. Zeldis","raw_affiliation_strings":["Celgene Corporation, Summit, New Jersey, USA. jzeldis@celgene.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, New Jersey, USA. jzeldis@celgene.com","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050333678","display_name":"Robert Knight","orcid":"https://orcid.org/0000-0001-9920-836X","observed_orcids":["https://orcid.org/0000-0001-9920-836X"]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Robert Knight","raw_affiliation_strings":["Celgene Corporation, Summit, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, New Jersey","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109563188","display_name":"Mohamad A. Hussein","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mohamad Hussein","raw_affiliation_strings":["Celgene Corporation, Summit, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, New Jersey","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111591940","display_name":"Rajesh Chopra","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Rajesh Chopra","raw_affiliation_strings":["Celgene Corporation, Summit, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, New Jersey","institution_ids":["https://openalex.org/I4387155837"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112281139","display_name":"George W. Muller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155837","display_name":"Celgene (United States)","ror":"https://ror.org/0527yg379","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4387155837"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"George Muller","raw_affiliation_strings":["Celgene Corporation, Summit, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celgene Corporation, Summit, New Jersey","institution_ids":["https://openalex.org/I4387155837"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5055075571"],"corresponding_institution_ids":["https://openalex.org/I4387155837"],"apc_list":{"value":5080,"currency":"USD","value_usd":5080},"apc_paid":null,"fwci":3.1948,"has_fulltext":false,"cited_by_count":81,"citation_normalized_percentile":{"value":0.92132793,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"1222","issue":"1","first_page":"76","last_page":"82"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9843999743461609,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9843999743461609,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.010700000450015068,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":1.0},{"id":"https://openalex.org/keywords/immunomodulators","display_name":"immunomodulators","score":0.906000018119812},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9980000257492065},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9100000262260437},{"id":"https://openalex.org/keywords/5q-deletion","display_name":"5q deletion","score":0.7670000195503235},{"id":"https://openalex.org/keywords/transfusion-independence","display_name":"transfusion independence","score":0.9120000004768372},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9179999828338623},{"id":"https://openalex.org/keywords/non-hodgkin-lymphoma","display_name":"non-Hodgkin lymphoma","score":0.9940000176429749},{"id":"https://openalex.org/keywords/prostate-cancer","display_name":"prostate cancer","score":0.9980000257492065},{"id":"https://openalex.org/keywords/hematologic-malignancies","display_name":"hematologic malignancies","score":0.9440000057220459},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6669999957084656},{"id":"https://openalex.org/keywords/oral-formulations","display_name":"oral dosage forms","score":0.5180000066757202}],"concepts":[{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.9857100248336792},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.7938953638076782},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7553871870040894},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.6445157527923584},{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.5768450498580933},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.5224775075912476},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4753971993923187},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.45986270904541016},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.45768821239471436},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.4415168762207031},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.33430224657058716},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.16974902153015137}],"mesh":[{"descriptor_ui":"D000077269","descriptor_name":"Lenalidomide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007155","descriptor_name":"Immunologic Factors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007155","descriptor_name":"Immunologic Factors","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D007155","descriptor_name":"Immunologic Factors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D007155","descriptor_name":"Immunologic Factors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049673","descriptor_name":"History, 20th Century","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049674","descriptor_name":"History, 21st Century","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055808","descriptor_name":"Drug Discovery","qualifier_ui":"Q000266","qualifier_name":"history","is_major_topic":false},{"descriptor_ui":"D055808","descriptor_name":"Drug Discovery","qualifier_ui":"Q000639","qualifier_name":"trends","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1749-6632.2011.05974.x","doi":"https://doi.org/10.1111/j.1749-6632.2011.05974.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1749-6632.2011.05974.x","pdf_url":null,"source":{"id":"https://openalex.org/S8802318","display_name":"Annals of the New York Academy of Sciences","issn_l":"0077-8923","issn":["0077-8923","1749-6632"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the New York Academy of Sciences","raw_type":"journal-article"},{"id":"pmid:21434945","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21434945","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the New York Academy of Sciences","raw_type":"Evaluation Study"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":44,"referenced_works":["https://openalex.org/W129466067","https://openalex.org/W1904757711","https://openalex.org/W1964370179","https://openalex.org/W1973532909","https://openalex.org/W1980068016","https://openalex.org/W1992538067","https://openalex.org/W1999088487","https://openalex.org/W2000069677","https://openalex.org/W2012721290","https://openalex.org/W2021333892","https://openalex.org/W2021954218","https://openalex.org/W2024698497","https://openalex.org/W2033556677","https://openalex.org/W2038048162","https://openalex.org/W2038308917","https://openalex.org/W2049869153","https://openalex.org/W2059873406","https://openalex.org/W2078761761","https://openalex.org/W2092961753","https://openalex.org/W2093539960","https://openalex.org/W2097331346","https://openalex.org/W2099308699","https://openalex.org/W2106233921","https://openalex.org/W2114492363","https://openalex.org/W2116194748","https://openalex.org/W2119810076","https://openalex.org/W2133986577","https://openalex.org/W2135404380","https://openalex.org/W2136242714","https://openalex.org/W2140256561","https://openalex.org/W2142149038","https://openalex.org/W2153558008","https://openalex.org/W2158313081","https://openalex.org/W2168929741","https://openalex.org/W2169336006","https://openalex.org/W2170210178","https://openalex.org/W2240601246","https://openalex.org/W2264583806","https://openalex.org/W2315184773","https://openalex.org/W2525909300","https://openalex.org/W2536796599","https://openalex.org/W2556427520","https://openalex.org/W2560547378","https://openalex.org/W4313376856"],"related_works":["https://openalex.org/W1499961308","https://openalex.org/W1613353577","https://openalex.org/W2000280591","https://openalex.org/W2350464447","https://openalex.org/W1977865587","https://openalex.org/W2462844398","https://openalex.org/W1998625437","https://openalex.org/W2945780367","https://openalex.org/W2995675641","https://openalex.org/W1974135782"],"abstract_inverted_index":{"Lenalidomide":[0],"(REVLIMID),":[1],"an":[2],"immunomodulatory":[3],"compound":[4],"targeting":[5],"both":[6],"cancer":[7],"cells":[8],"and":[9,64,85,115,125,134],"their":[10],"microenvironment,":[11],"has":[12,80],"substantial":[13],"activity":[14],"in":[15,47,100,126],"several":[16,35],"difficult-to-manage":[17],"hematological":[18,130],"malignancies.":[19],"In":[20,52],"previously":[21],"treated":[22],"multiple":[23,50],"myeloma,":[24],"lenalidomide":[25,45,69,123],"produces":[26],"high-quality":[27],"responses":[28],"combined":[29],"with":[30,55,59],"sustained":[31],"disease":[32],"control.":[33],"Recently,":[34],"randomized":[36],"studies":[37,120],"have":[38],"demonstrated":[39],"a":[40,65,81],"clinical":[41],"benefit":[42],"of":[43,77],"continuous":[44],"treatment":[46],"newly":[48],"diagnosed":[49],"myeloma.":[51],"many":[53],"patients":[54],"refractory":[56],"anemia":[57],"associated":[58],"lower":[60],"risk":[61],"myelodysplastic":[62],"syndromes":[63],"5q":[66],"chromosome":[67],"deletion,":[68],"leads":[70],"to":[71],"transfusion":[72],"independence,":[73],"considerably":[74],"improving":[75],"quality":[76],"life.":[78],"It":[79],"manageable":[82],"safety":[83],"profile,":[84],"its":[86],"oral":[87],"formulation":[88],"reduces":[89],"the":[90],"burden":[91],"on":[92],"patients.":[93],"Several":[94,118],"phase":[95],"III":[96],"trials":[97],"are":[98,121],"ongoing":[99],"other":[101],"indications":[102],"currently":[103],"underserved":[104],"by":[105],"conventional":[106],"therapy,":[107],"such":[108],"as":[109],"chronic":[110],"lymphocytic":[111],"leukemia,":[112],"non-Hodgkin's":[113],"lymphoma,":[114],"prostate":[116],"cancer.":[117],"early-stage":[119],"exploring":[122],"alone":[124],"combination":[127],"across":[128],"different":[129],"malignancies,":[131],"solid":[132],"tumors,":[133],"immune-related":[135],"disorders.":[136]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2166959486","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":10}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
